Publications by authors named "Mohit Butaney"

39Publications

Quality of Bladder Cancer Information on YouTube.

Eur Urol 2020 Sep 30. Epub 2020 Sep 30.

Department of Urology, University of North Carolina, Chapel Hill, NC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2020.09.014DOI Listing
September 2020

Vasoepididymostomy: an insight into current practice patterns.

Transl Androl Urol 2019 Dec;8(6):728-735

Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tau.2019.11.04DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6987588PMC
December 2019

Twitter response to the 2018 US Preventive Services Task Force guidelines on prostate cancer screening.

BJU Int 2019 09 27;124(3):363-364. Epub 2019 Mar 27.

Department of Urology, New York University School of Medicine, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bju.14734DOI Listing
September 2019

Accuracy of the magnetic resonance imaging pathway in the detection of prostate cancer: a systematic review and meta-analysis.

Prostate Cancer Prostatic Dis 2019 03 14;22(1):39-48. Epub 2018 Aug 14.

University of Melbourne, Department of Surgery, Urology Unit and Olivia Newton-John Cancer Centre, Austin Health, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41391-018-0075-4DOI Listing
March 2019

The utility of PET-based imaging for prostate cancer biochemical recurrence: a systematic review and meta-analysis.

World J Urol 2019 Jul 12;37(7):1239-1249. Epub 2018 Jul 12.

Department of Urology, University of Minnesota, MMC 394, Minneapolis, MN, 55455, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00345-018-2403-7
Publisher Site
http://dx.doi.org/10.1007/s00345-018-2403-7DOI Listing
July 2019

Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer.

J Thorac Oncol 2015 Dec;10(12):1726-35

*Department of Medical Oncology, †Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; ‡Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts; §Harvard Medical School, Boston, Massachusetts; ‖Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts. ¶Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts; and #Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000687DOI Listing
December 2015

Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2.

Cancer Res 2015 Aug 5;75(15):3139-46. Epub 2015 Jun 5.

Lowe Center for Thoracic Oncology, Boston, Massachusetts. Department of Medical Oncology, Boston, Massachusetts. Department of Medicine, Boston, Massachusetts. Belfer Institute for Applied Cancer Science, Dana Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-14-3771DOI Listing
August 2015

Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.

Clin Cancer Res 2015 Jun 3;21(12):2851-60. Epub 2015 Mar 3.

Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-3112DOI Listing
June 2015

Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.

Cancer Discov 2013 Dec 27;3(12):1355-63. Epub 2013 Sep 27.

Departments of 1Medicine and 2Medical Oncology and Cancer Vaccine Center, Dana-Farber Cancer Institute; 3Harvard Medical School; 4Ludwig Institute for Cancer Research; 5Department of Neurosurgery, Massachusetts General Hospital; 6Belfer Institute for Applied Cancer Science; 7Department of Pathology, Brigham and Women's Hospital, Boston; 8Broad Institute, Cambridge, Massachusetts; 9UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; and 10Department of Molecular Pharmacology and Therapeutics, Oncology Institute, Loyola University, Chicago, Illinois; 11Department of Physiology, University of Valencia, Valencia, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0310DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3864135PMC
December 2013

ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas.

Am J Surg Pathol 2013 Sep;37(9):1441-9

*Department of Pathology, Brigham and Women's Hospital †Lowe Center for Thoracic Oncology ‡Belfer Institute for Applied Cancer Science, Dana Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0b013e3182960fa7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3831351PMC
September 2013

The introduction of systematic genomic testing for patients with non-small-cell lung cancer.

J Thorac Oncol 2012 Dec;7(12):1767-1774

Department of Medical Oncology, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts; Department of Medicine, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e3182745bcbDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3500523PMC
December 2012